Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict

Eli Lilly’s cancer drug Cyramza has inched closer to a new indication in first-line non-small cell lung cancer (NSCLC), after a narrow vote in favour of approval by FDA advisors.